Literature DB >> 8405317

Duration of the immune response to MMR vaccine in children of two age-different groups.

S Li Volti1, G Giammanco-Bilancia, M Grassi, R Garozzo, R Gluck, G Giammanco.   

Abstract

A combined vaccine against measles, mumps and rubella (MMR) was administered to both a group of children aged 10-12 months simultaneously with booster doses of compulsory diphtheria-tetanus toxoids and oral poliovirus vaccine and a group of children aged 15-24 months who had previously received booster doses of the compulsory vaccines. Apart from one subject belonging to the second group who was non responder and one from the same group who did not seroconvert against the mumps virus alone, 5 to 6 weeks after MMR vaccine administration we found protective levels of antibodies against measles, mumps and rubella viruses in all children. The follow up of both groups at 3 years did not reveal difference between the two groups. Protective levels of serum antibodies against measles and mumps were found in the two groups, although a significant decline of rubella antibodies was shown (p < 0.05). Since the immunogenicity of the vaccines in the two groups did not differ, we recommend that the scientific community reconsider the vaccination schedule until now recommended. In our opinion the MMR vaccine should be administered simultaneously with booster doses of diphtheria-tetanus toxoids and oral poliovirus vaccine at 10-12 months of age because this policy improves parents' compliance, markedly reduces community costs and simplifies routine immunization schedule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405317     DOI: 10.1007/bf00146269

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

1.  Present status of measles and rubella immunization in the United States: a medical progress report.

Authors:  S Krugman
Journal:  J Pediatr       Date:  1977-01       Impact factor: 4.406

2.  Serological evidence of reinfection among vaccinees during rubella outbreak.

Authors:  M G Cusi; G M Rossolini; P E Valensin; C Cellesi; A Zanchi
Journal:  Lancet       Date:  1990-10-27       Impact factor: 79.321

3.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure.

Authors:  P Albrecht; F A Ennis; E J Saltzman; S Krugman
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

Review 4.  Duration of live measles vaccine-induced immunity.

Authors:  L E Markowitz; S R Preblud; P E Fine; W A Orenstein
Journal:  Pediatr Infect Dis J       Date:  1990-02       Impact factor: 2.129

5.  Serological evaluation of a measles, mumps, and rubella vaccine.

Authors:  C M Robertson; V J Bennett; N Jefferson; R T Mayon-White
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791

6.  Combined live measles, mumps, and rubella virus vaccines.

Authors:  E B Buynak; R E Weibel; J E Whitman; J Stokes; M R Hilleman
Journal:  JAMA       Date:  1969-03-24       Impact factor: 56.272

7.  Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.

Authors:  H Peltola; V Karanko; T Kurki; V Hukkanen; M Virtanen; K Penttinen; M Nissinen; O P Heinonen
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

Review 8.  Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months.

Authors:  J S Marks; G F Hayden; W A Orenstein
Journal:  Am J Epidemiol       Date:  1982-09       Impact factor: 4.897

9.  Persistence of rubella antibody 8-18 years after vaccination.

Authors:  S O'Shea; J M Best; J E Banatvala; W C Marshall; J A Dudgeon
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-07

10.  Benefits, risks and costs of immunization for measles, mumps and rubella.

Authors:  C C White; J P Koplan; W A Orenstein
Journal:  Am J Public Health       Date:  1985-07       Impact factor: 9.308

View more
  2 in total

Review 1.  [Mumps vaccines: virological basis].

Authors:  A Ströhle; D Germann
Journal:  Soz Praventivmed       Date:  1995

Review 2.  Mumps Outbreaks in Vaccinated Populations-Is It Time to Re-assess the Clinical Efficacy of Vaccines?

Authors:  Anna R Connell; Jeff Connell; T Ronan Leahy; Jaythoon Hassan
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.